Ketamine’s antianhedonic effect is an active area of investigation considering that preclinical studies suggest a synergistic effect of ketamine and lithium, highlighting activation of the mTOR pathway and GSK-3 inhibition, thus improving both depression–anhedonia and suicidality [40]. The gene discussed is MTOR; the disease is depressive symptom measurement.